¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Sodium Channel Blockers"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gated channel
    °ü¹®Åë·Î
  • ion channel disorder
    ÀÌ¿ÂÅë·ÎÁúȯ
  • voltage gated channel
    Àü¾ÐÀÛµ¿Åë·Î
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • parallel channel sign
    ÆòÇà°ü¡ÈÄ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hepatocardiac channel
    °£½ÉÀå__ÊÜãýíôϵ).
  • ion channel
    À̿ Åë·Î
  • ion channel
    ÀÌ¿ÂÅë·Î.
  • ion channel
    ÀÌ¿ÂÅë·Î(÷×ÖØ).
  • ion channel blocker
    ÀÌ¿ÂÅë·ÎÂ÷´ÜÁ¦
  • lymph channel
    ¸²ÇÁ°ü(¡­Î·).
  • maltose channel (lamda receptor)
    ¸»Å佺Åë·Î (¶÷´Ù¼ö¿ëü)
  • outflow channel
    ¹æ¼öÀ¯Ãâ·Î
  • parallel channel sign
    ÆòÇà°ü ¡ÈÄ
  • porin channel
    Æ÷¸°Åë·Î
  • potassium channel
    Ä®·ýÅë·Î
  • pyloric channel
    À¯¹®Åë·Î.
  • signal channel
    ½ÅÈ£ Åë·Î
  • transmembrane channel
  • two-channel method
    2 ¼ÒÀÚ¹ý (ì£ áÈí­Ûö)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SB Bachelor of Science; Schwartz-Bartter [syndrome]; serum bilirubin; shortness of breath; sick bay; si...
SPS scapuloperoneal syndrome; shoulder pain and stiffness; simple partial seizures; slow-progressive sch...
STS sequence tagged site; serologic test for syphilis; sodium tetradecyl sulfate; sodium thiosulfate; st...
ROC Receptor Operated Channel
VSC Voltage Sensitive Channel
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CRC Ca(2+)-release channel
CRC Calcium Release Channel
CCA Calcium channel antagonists
CCB Calcium channel blocker
CCV Channel Catfish virus
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • exsiccated sodium phosphate
    °ÇÁ¶ ÀÎ»ê ³ªÆ®·ý
  • Harlmann sodium lactate solution
    Á¥»ê ³ªÆ®·ý ¿ë¾×, Çϸ£Æ®¸¸ ¿ë¾×, À¯»ê ³ªÆ®·ý ¿ë¾×
  • hexobarbital sodium
    Çí»ç¹Ù¸£ºñÅ» ³ªÆ®·ý
  • meralluride sodium
    ¸Þ¶ö·ç¶óÀÌµå ³ªÆ®·ý
  • morrhuate sodium : °£À¯ÀÇ Áö¹æ»ê ³ªÆ®·ý¿°. °æÈ­Á¦·Î¼­ ƯÈ÷ Á¤¸Æ·ù ¹× Ä¡ÁúÀÇ Ä¡·á¿¡ »ç¿ëµÇ¸ç Á¤¸Æ·ù ³»·Î ¿ë¾×À» ÁÖ»çÇÑ´Ù.

    morrhuic acid

    ¸ð·çÀλê
  • naproxen sodium

    naprylate (³ªÇÁ¸±·¹ÀÌÆ®

    ÇǺΠÁø±ÕÁõÀÇ Ä¡·áÁ¦.
  • serum sodium
    Ç÷û ³ªÆ®·ý
  • sodium
    ³ªÆ®·ý
    ¹é»öÀÇ ¾ËÄ®¸®¼º ±Ý¼Ó ¿ø¼Ò, Na, ¿øÀÚ ¹øÈ£ 11, ¿øÀÚ·® 22.990, ºñÁß 0.971, ¿øÀÚ°¡ 1.
  • sodium alginate
    ¾ËÁø»ê ³ªÆ®·ý
    ¾à ¾ËÄ®¸®¸¦ »ç¿ëÇÏ¿© °¥»ö ÇØÃʷκÎÅÍ ÃßÃâ Á¤Á¦µÈ ź¼öÈ­¹° ÇöŹ¾× ¿ëÁ¦·Î ¾²ÀδÙ. ¶ÇÇÑ À¯È­ ÀÛ¿ë, ¾ÈÁ¤È­ ÀÛ¿ë, ³óÈ­ ÀÛ¿ë, ¼ö°áÇÕ ÀÛ¿ëÀ» °¡ÁüÀ¸·Î½á À½½Ä¹°, ÀǾàǰ, È­Àåǰ µî¿¡ »ç¿ëµÈ´Ù.
  • sodium benzoate
    ¾È½ÄÇâ»ê ³ªÆ®·ý
    ¾È½ÄÇâ»êÀÇ ³ªÆ®·ý¿°. ¹é»öÀÇ °ú¸³»ó ¶Ç´Â °áÁ¤¼º ºÐ¸». Ç×Áø±Õ¼º ¾àǰ. °£ ±â´É °Ë»ç¿ëÀ¸·Î »ç¿ëµÈ´Ù.
  • sodium biphosphate
    ÀÌÀÎ»ê ³ªÆ®·ý
    ÀλêÀÇ monohydrate ÀÏ ³ªÆ®·ý¿°. ¹«»öÀÇ °áÁ¤ ¶Ç´Â ¹é»öÀÇ °áÁ¤¼º ºÐ¸». Ç×Ä®½· °úÀ× Ç÷Á¦, ¼³»ç ¾àÀ¸·Î¼­ ÀÎ»ê ³ªÆ®·ý°ú ÇÔ²² Åõ¿©µÈ´Ù. ¿äÀÇ »ê¼ºÈ­Á¦·Îµµ ¾²ÀδÙ.
  • sodium bisulfite
    Áß¾ÆÈ²»ê ³ªÆ®·ý
    ¾ÆÈ²»ê ¼ö¼Ò ³ªÆ®·ý. ¿©·¯ °¡ÁöÀÇ Á¦¾à¿¡ Ç×»êÈ­Á¦·Î »ç¿ëµÈ´Ù.
  • sodium carbonate
    ź»ê ³ªÆ®·ý
    ¹«»öÀÇ °áÁ¤ ¶Ç´Â ¹é»öÀÇ °áÁ¤¼º ºÐ¸». Á¦¾×¿¡¼­ ¾ËÄ®¸®È­ ¾àǰÀ¸·Î »ç¿ëÇÑ´Ù. ¶ÇÇÑ Àμ³À» ÀÏÀ¸Å°´Â ÇǺκ´ÀÇ Ä¡·á¿¡ »ç¿ëÇϸç, ¼¼Á¤Á¦·Îµµ ¾²ÀδÙ.
  • sodium citrate
    ±¸¿¬»ê ³ªÆ®·ý
    C6H5Na3O7. ±¸¿¬»êÀÇ »ï³ªÆ®·ý¿°.
  • sodium exchange resin
    ³ªÆ®·ý ±³È¯ ¼öÁö, ¼Òµð¿ò ±³È¯ ¼öÁö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
channel transport <radiobiology> In inertial fusion research using light ion drivers, describes the use of current-carrying plasma channels (which are magnetically confined to the channel) to transport electron or ion beams between the ion diode and the fusion target. This allows the ion source to stand back from the target.
(09 Oct 1997)
chloride channel Ion channels selective for chloride ions. Various types including ligand activated Cl channels at synapses (the GABA and glycine activated channels), as well as voltage gated Cl channels found in a variety of plant and animal cells.
See: CFTR, MDR.
(18 Nov 1997)
ryanodine receptor calcium release channel Protein complexes that mediate the release of calcium from the sarcoplasmic reticulum in both skeletal and cardiac muscle cells by forming tetrametric complexes. These complexes each then act as a calcium channel. There are three isoforms of the ryr: ryr1, ryr2, and ryr3. Ryr1 is specifically expressed in skeletal muscles and ryr2 in cardiac muscles. Ryr3 is yet another isoform found in non-muscle cells such as neuronal cells.
(12 Dec 1998)
potassium channel Ion channel selective for potassium ions. There are diverse types with different functions, for example: delayed rectifier channels, M channels, A channels, inward rectifier channels, Ca dependent K channels.
(18 Nov 1997)
single channel recording Variant of patch clamp technique.
(18 Nov 1997)
slow channel-blocking agent calcium channel-blocking agent
delayed rectifier channel <physiology> The potassium selective ion channels of axons, so called because they change the potassium conductance with a delay after a voltage step.
The name is used to denote any axon like K channel. Various roles for example regulation of pacemaker potentials, generation of bursts of action potentials or generation of long plateaus on action potentials.
(18 Nov 1997)
double-channel catheter A catheter with two lumens, allowing irrigation and aspiration.
Synonym: two-way catheter.
(05 Mar 2000)
ion channel <cell biology> A transmembrane pore that presents a hydrophilic channel for ions to cross a lipid bilayer down their electrochemical gradients.
Some degree of ion specificity is usually observed and typically a million ions per second may flow. Channels may be permanently open, like the potassium leak channel or they may be voltage gated, like the sodium channel or ligand gated like the acetylcholine receptor.
(27 Oct 1998)
ion channel gating The opening and closing of ion channels due to a stimulus. The stimulus can be a change in membrane potential (voltage-gated), drugs or chemical transmitters (ligand-gated), or a mechanical deformation. Gating is thought to involve conformational changes of the ion channel which alters selective permeability.
(12 Dec 1998)
transnexus channel A hexagonal 15-20A
ligand-gated channel A class of ion channel's whose ionic permeability is regulated by cell membrane receptors that respond to specific extracellular chemical signals.
(05 Mar 2000)
ligand gated ion channel A transmembrane ion channel whose permeability is increased by the binding of a specific ligand, typically a neurotransmitter at a chemical synapse. The permeability change is often drastic, such channels let through effectively no ions when shut, but allow passage at up to 10exp7 ions sexp 1 when a ligand is bound. Recently, the receptors for both acetylcholine and GABA have been found to share considerable sequence homology, implying that there may be a family of structurally related ligand gated ion channels.
(18 Nov 1997)
acetosulfone sodium 2-N-Acetylsulfamyl-4,4'-diaminodiphenylsulfone;a leprostatic administered orally.
(05 Mar 2000)
acetrizoate sodium Salt of 3-acetamido-2,4,6-triiobenzoic acid, a formerly used water-soluble radiographic contrast medium.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • channel
    °­¹Ù´Ú;ÇÏ»ó;À¯»ó;¼ö·Î;°¡Ç×¼ö·Î;¿îÇÏ;ÇØÇù;(º¸µµ,¹«¿ª µîÀÇ)°æ·Î;·çÆ®;°èÅë;(Á¤½Ä)Àü´Þ ·çÆ®;(¿Õº¹ µîÀÇ)°æ·Î;(¶óµð¿À.ÅÚ·¹ºñÀü µîÀÇ)ä³Î;(ÇÒ´çµÈ)Á֯ļö´ë;(»ç»ó.Çൿ µîÀÇ)¹æÇâ;¹æÄ§;(Ȱµ¿ÀÇ)ºÐ¾ß;(µµ·ÎÀÇ)µµ¶û;Ãø±¸;¾Ï°Å;¼Ò°ü;µµ°ü;(¹®Áö¹æ µîÀÇ Àå½ÄȨ,(ÀϹÝÀûÀ¸·Î) °¡
  • channel iron (bar)
    Ȩ¼è(UÀÚ ¸ð¾çÀÇ ¼â.¸ø) a
  • channel lease
    ä³Î¸®½º(À¯¼± TVÀÇ ºó ä³ÎÀÇ ´ë¿©(Â÷¿ë))
  • channel separation
    ä³ÎºÐ¸®
  • channel(l)ed
    ȨÀÌ ÀÖ´Â
  • cross-channel
    ÇØÇùȾ´ÜÀÇ;ÇØÇùÀÇ ¸ÂÀº Æí ÂÊÀÇ(ƯÈ÷ ¿µ±¹ ÇØÇùÀÇ)
  • idiot channel
    ¹Î°£ ÅÚ·¹ºñÁ¯ ¹æ¼Û
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á